Acrivon Therapeutics, Inc

Contributing Author

Recent Articles by Acrivon Therapeutics, Inc

Oct-22	Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference ACRV GlobeNewswire
Oct-01	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACRV GlobeNewswire
Aug-13	Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights ACRV GlobeNewswire
May-14	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights ACRV GlobeNewswire